Tepotinib + Gefitinib (TEP+GEF) in MET+/epidermal Growth Factor Receptor (Egfr)-Mutant Non-Small Lung Cancer (NSCLC): Phase II Data
Y-L. Wu,J. Zhou,S. Lu,Y. Zhang,J. Zhao,H. Pan,Y-M. Chen,C-F. Chian,R. Bruns,A. Johne,J. Scheele,Y. Cheng
DOI: https://doi.org/10.1093/annonc/mdy425.026
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: MET amplification (amp) may cause acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC; dual Met/EGFR inhibition has potential in EGFR TKI-resistant NSCLC. We report ph2 data from a randomized ph1b/2 trial of TEP (potent, selective Met TKI) + GEF vs chemotherapy (CT: pemetrexed + cisplatin/carboplatin) in Asian patients (pts) with MET+/EGFR+T790M- NSCLC and a single-arm cohort of TEP+GEF in Chinese pts with MET+/EGFR+T790M+ NSCLC. Methods: Pts with advanced EGFR+ and MET + (IHC2+/3+, gene amp) NSCLC, acquired resistance to 1L EGFR TKI and ECOG PS 0–1 were randomized to receive TEP+GEF 500/250 mg QD or CT. Primary endpoint: PFS (investigator). Secondary endpoints: safety, objective response rate, PFS (IRC; randomized). Results: Low recruitment halted enrolment. To 12 June 2017, 55/156 planned MET+ T790M- pts (TEP+GEF n = 31; CT n = 24) were randomized and 15 MET+ T790M+ pts included (28/70 men, median age 60.4 [range 42, 82] y). Median TEP+GEF treatment duration: randomized 21.4 (range 4.6, 91.9) wks; single-arm 6.3 (3, 40) wks. In MET+ T790M- pts, a numeric trend favored TEP+GEF vs CT for PFS (HR: 0.71 [90% CI 0.36, 1.39]; Table). High IHC (IHC3+:0.35 [0.17, 0.74]) and MET amp (0.17 [0.05, 0.57]) favored improved PFS. Antitumor activity was limited in the single-arm MET+ T790M+ group (median PFS 1.4 months [90% CI 1.4, 4.9] BOR SD in 40% pts). In randomized pts (MET+ T790M-), 3 (TEP+GEF) vs 1 (CT) had treatment-emergent adverse events (TEAEs) leading to permanent treatment discontinuation, 1 vs 0 had TEAEs leading to death (0 trial drug-related), 5 vs 7 had serious trial-drug related TEAEs, 16 vs 12 had Grade ≥3 trial-drug related TEAEs, 4 vs 2 had a trial-drug related TEAE of special interest (lipase/amylase increase ≥3). Safety in the single-arm grouTable515POverall intent-to-treat (MET + [IHC 2+/IHC 3+/gene amplification]/EGFR T790M-) (N = 55)Tepotinib + gefitinib (n = 31)Pemetrexed + cisplatin/carboplatin (n = 24)Median PFS [90% CI], months, investigator4.9 [3.9, 6.9]4.4 [4.2, 6.8]Stratified HR 0.71 [90% CI 0.36, 1.39]Median PFS [90% CI], months, IRC10.2 [4.2, 19.8]4.4 [4.2, 7.0]Stratified HR 0.56 [90% CI 0.24, 1.27]ORR, investigator, n (%) [90% CI]14 (45.2) [29.7, 61.3]8 (33.3) [17.8, 52.1]Adjusted OR 1.99 [90% CI 0.56, 6.87]IHC3+/EGFR T790M- (n = 34)Tepotinib + gefitinib (n = 19)Pemetrexed + cisplatin/carboplatin (n = 15)Median PFS [90% CI], months, investigator8.3 [4.1, 21.2]4.4 [4.1, 6.8]Unstratified HR 0.35 [90% CI 0.17, 0.74]Median PFS [90% CI], months, IRC10.2 [5.6, 19.8]4.4 [4.2, 7.0]Unstratified HR 0.30 [90% CI 0.12, 0.77]ORR, investigator, n (%) [90% CI]13 (68.4) [47.0, 85.3]5 (33.3) [14.2, 57.7]OR 4.33 [90% CI 1.03, 18.33]Gene amplification (GCN ≥5 or MET/CEP7 ratio ≥2/EGFR T790M- (n = 19)Tepotinib + gefitinib (n = 12)Pemetrexed + cisplatin/carboplatin (n = 7)Median PFS [90% CI], months, investigator21.2 [8.3, 21.2]4.2 [1.4, 7.0]Unstratified HR 0.17 [90% CI 0.05, 0.57]Median PFS [90% CI], months, IRC19.8 [5.6, 19.8]5.5 [1.4, 7.0]Unstratified HR 0.25 [90% CI 0.07, 0.85]ORR, investigator, n (%) [90% CI]8 (66.7) [39.1, 87.7]3 (42.9) [12.9, 77.5]OR 2.67 [90% CI 0.37, 19.56]MET+: Met overexpression by immunohistochemistry (IHC2+ or 3+) and/or MET gene amplification and/or increased gene copy number (GCN ≥5 or MET/CEP7 ratio ≥2) by in-situ hybridization IRC, independent review committee; OR, odds ratio; ORR, objective response rate; PFS, progression-free survival. Open table in a new tab p was similar. MET+: Met overexpression by immunohistochemistry (IHC2+ or 3+) and/or MET gene amplification and/or increased gene copy number (GCN ≥5 or MET/CEP7 ratio ≥2) by in-situ hybridization IRC, independent review committee; OR, odds ratio; ORR, objective response rate; PFS, progression-free survival. Conclusions: TEP+GEF has promising antitumor activity in Met protein overexpression and gene-amp MET+/EGFR+T790M-NSCLC pts and was generally well-tolerated. Editorial acknowledgement: Lisa Jolly. Clinical trial identification: NCT01982955. Legal entity responsible for the study: Merck KGaA. Funding: Merck KGaA. Disclosure: S. Lu: Research support: AstraZeneca; Speaker fees: AstraZeneca, Eli Lilly, Roche, Pfizer; Advisor, consultant: AstraZeneca, Hutchison MediPharma, Simcere, BMS, Roche, Pfizer. R. Bruns: Employment, shares: Merck, KGaA. A. Johne, J. Scheele: Employment: Merck KGaA, Darmstadt, Germany. Y-L. Wu: Speaker fees: AstraZeneca, Eli Lilly, Pfizer, Roche, Sanofi. All other authors have declared no conflicts of interest.